MedTrace Logo

Prospective Tumor Response Evaluation

NCT02787954 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2018-10-18

No results posted yet for this study

Summary

The purpose of this study is to determine if MRI imaging can detect genetic, proteomic, and metabolomic characteristics of liver tumors. The study also aims to determine if these imaging characteristics are correlated with clinical outcomes.

Conditions

  • Hepatocellular Cancer
  • Metastatic Liver Cancer

Interventions

PROCEDURE

TACE

Procedure for giving chemotherapy directly to tumor cells.

PROCEDURE

Y-90

Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.

PROCEDURE

MWA

Using heat to kill tumor cells.

PROCEDURE

IRE

Using energy to disrupt tumor cell activity, thereby causing cellular death.

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Derek L West, MD · University of Texas Healtlh Science Center at Houston

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02787954 on ClinicalTrials.gov